PLx Pharma Inc. announced the addition of Efthymios N. Deliargyris as Chief Medical Advisor. Dr. Deliargyris, an internationally-recognized expert in the field of thrombosis, brings to the company deep knowledge in cardiovascular medicine and extensive experience in the development and commercialization of antithrombotic agents. In his new role, he will oversee critical scientific and medical affairs activities that are expected to advance the market readiness of U.S. Food and Drug Administration (FDA) approved Aspertec 325 mg, a liquid-filled aspirin capsule for over-the-counter distribution.